Clinical Pharmacokinetic Studies in Pregnant Women and the Relevance of Pharmacometric Tools

Author(s): André Dallmann*, Paola Mian, Johannes Van den Anker, Karel Allegaert.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 5 , 2019

Abstract:

Background: In clinical pharmacokinetic (PK) studies, pregnant women are significantly underrepresented because of ethical and legal reasons which lead to a paucity of information on potential PK changes in this population. As a consequence, pharmacometric tools became instrumental to explore and quantify the impact of PK changes during pregnancy.

Methods: We explore and discuss the typical characteristics of population PK and physiologically based pharmacokinetic (PBPK) models with a specific focus on pregnancy and postpartum.

Results: Population PK models enable the analysis of dense, sparse or unbalanced data to explore covariates in order to (partly) explain inter-individual variability (including pregnancy) and to individualize dosing. For population PK models, we subsequently used an illustrative approach with ketorolac data to highlight the relevance of enantiomer specific modeling for racemic drugs during pregnancy, while data on antibiotic prophylaxis (cefazolin) during surgery illustrate the specific characteristics of the fetal compartments in the presence of timeconcentration profiles. For PBPK models, an overview on the current status of reports and papers during pregnancy is followed by a PBPK cefuroxime model to illustrate the added benefit of PBPK in evaluating dosing regimens in pregnant women.

Conclusions: Pharmacometric tools became very instrumental to improve perinatal pharmacology. However, to reach their full potential, multidisciplinary collaboration and structured efforts are needed to generate more information from already available datasets, to share data and models, and to stimulate cross talk between clinicians and pharmacometricians to generate specific observations (pathophysiology during pregnancy, breastfeeding) needed to further develop the field.

Keywords: Pregnancy, pharmacometrics, perinatal pharmacology, population-pharmacokinetic modeling, physiologically-based pharmacokinetic modeling, ketorolac data.

[1]
O’Hare MF, Leahey W, Murnaghan GA, McDevitt DG. Pharmacokinetics of sotalol during pregnancy. Eur J Clin Pharmacol 1983; 24(4): 521-4.
[2]
Philipson A, Stiernstedt G, Ehrnebo M. Comparison of the pharmacokinetics of cephradine and cefazolin in pregnant and non-pregnant women. Clin Pharmacokinet 1987; 12(2): 136-44.
[3]
Heikkilä A, Erkkola R. Pharmacokinetics of piperacillin during pregnancy. J Antimicrob Chemother 1991; 28(3): 419-23.
[4]
Eyal S, Easterling TR, Carr D, et al. Pharmacokinetics of metformin during pregnancy. Drug Metab Dispos 2010; 38(5): 833-40.
[5]
Yerby MS, Friel PN, McCormick K, et al. Pharmacokinetics of anticonvulsants in pregnancy: Alterations in plasma protein binding. Epilepsy Res 1990; 5(3): 223-8.
[6]
Zheng S, Easterling TR, Umans JG, et al. Pharmacokinetics of tacrolimus during pregnancy. Ther Drug Monit 2012; 34(6): 660-70.
[7]
Quattrochi LC, Vu T, Tukey RH. The human CYP1A2 gene and induction by 3-methylcholanthrene. A region of DNA that supports AH-receptor binding and promoter-specific induction. J Biol Chem 1994; 269(9): 6949-54.
[8]
Lai KP, Wong MH, Wong CK. Modulation of AhR-mediated CYP1A1 mRNA and EROD activities by 17beta-estradiol and dexamethasone in TCDD-induced H411E cells. Toxicol Sci 2004; 78(1): 41-9.
[9]
Brazier JL, Ritter J, Berland M, Khenfer D, Faucon G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther 1983; 6(5): 315-22.
[10]
Gardner MJ, Schatz M, Cousins L, Zeiger R, Middleton E, Jusko WJ. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline. Eur J Clin Pharmacol 1987; 32(3): 289-95.
[11]
Dempsey D, Jacob P III, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther 2002; 301(2): 594-8.
[12]
Högstedt S, Lindberg B, Peng DR, Regårdh CG, Rane A. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 1985; 37(6): 688-92.
[13]
Rey E, d’Athis P, Giraux P, et al. Pharmacokinetics of clorazepate in pregnant and non-pregnant women. Eur J Clin Pharmacol 1979; 15(3): 175-80.
[14]
Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: A University of Washington specialized center of research study. Clin Pharmacol Ther 2008; 84(2): 248-53.
[15]
Nylén H, Sergel S, Forsberg L, et al. Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. Eur J Clin Pharmacol 2011; 67(7): 715-22.
[16]
Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig 2004; 11(7): 438-48.
[17]
Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 2013; 41(2): 256-62.
[18]
Stek AM, Best BM, Luo W, et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med 2012; 13(4): 226-35.
[19]
Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011; 205(1): 51.e1-8.
[20]
Lupattelli A, Spigset O, Twigg MJ, et al. Medication use in pregnancy: A cross-sectional, multinational web-based study. BMJ Open 2014; 4(2): e004365.
[21]
Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: An analysis of 18,000 prescriptions in Liverpool Women’s Hospital. Int J Pharm Pract 2010; 18(4): 226-9.
[22]
Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191(2): 398-407.
[23]
Gagne JJ, Maio V, Berghella V, Louis DZ, Gonnella JS. Prescription drug use during pregnancy: A population-based study in Regione Emilia-Romagna, Italy. Eur J Clin Pharmacol 2008; 64(11): 1125-32.
[24]
McCormack SA, Best BM. Obstetric Pharmacokinetic Dosing Studies are Urgently Needed. Front Pediatr 2014; 2: 9.
[25]
Baylis F. Pregnant women deserve better. Nature 2010; 465(7299): 689-90.
[26]
Faden R, Drapkin Lyerly A, Little M. A Custom Drug New York Times. 2009.
[27]
Endicott S, Haas DM. The current state of therapeutic drug trials in pregnancy. Clin Pharmacol Ther 2012; 92(2): 149-50.
[28]
Michelet R, Bocxlaer JV, Vermeulen A. PBPK in Preterm and Term Neonates: A Review. Curr Pharm Des 2017; 23(38): 5943-54.
[29]
Zeilmaker GA, Pokorna P, Mian P, et al. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients. Expert Opin Drug Metab Toxicol 2018; 14(4): 417-28.
[30]
Admiraal R, van Kesteren C, Boelens JJ, Bredius RG, Tibboel D, Knibbe CA. Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling. Arch Dis Child 2014; 99(3): 267-72.
[31]
Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment for children: Creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 2009; 14(5-6): 316-20.
[32]
Allegaert K, Olkkola KT, Owens KH, Van de Velde M, de Maat MM, Anderson BJ. Covariates of intravenous paracetamol pharmacokinetics in adults. BMC Anesthesiol 2014; 14: 77.
[33]
Standing JF, Anderson BJ, Holford NH, Lutsar I, Metsvaht T. Comment on pharmacokinetic studies in neonates: The utility of an opportunistic sampling design. Clin Pharmacokinet 2015; 54(12): 1287-8.
[34]
Østensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 2006; 8(3): 209.
[35]
Feng S, Shi J, Parrott N, et al. Combining ‘Bottom-Up’ and ‘Top-Down’ methods to assess ethnic difference in clearance: bitopertin as an example. Clin Pharmacokinet 2016; 55(7): 823-32.
[36]
Teorell T. Kinetics of distribution of substances administered to the body, I: The extravascular modes of administration. Arch Int Pharmacodyn Ther 1937; 57: 205-25.
[37]
Teorell T. Kinetics of distribution of substances administered to the body, II: the intravascular modes of administration. Arch Int Pharmacodyn Ther 1937; 57: 226-40.
[38]
Bellman R. JJA, Kalaba R. Some mathematical aspects of chemotherapy: I. One-organ models. Bull Math Biol 1960; 22: 181-98.
[39]
Jacquez JABR, Kalaba R. Some mathematical aspects of chemotherapy-II: The distribution of a drug in the body. Bull Math Biol 1960; 22: 309-22.
[40]
Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci 1971; 60(8): 1128-33.
[41]
Benowitz N, Forsyth FP, Melmon KL, Rowland M. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model. Clin Pharmacol Ther 1974; 16(1): 87-98.
[42]
Tsuji A, Miyamoto E, Terasaki T, Yamana T. Physiological pharmacokinetics of beta-lactam antibiotics: penicillin V distribution and elimination after intravenous administration in rats. J Pharm Pharmacol 1979; 31(2): 116-9.
[43]
Olanoff LS, Anderson JM. Controlled release of tetracycline--III: A physiological pharmacokinetic model of the pregnant rat. J Pharmacokinet Biopharm 1980; 8(6): 599-620.
[44]
Gabrielsson JL, Paalzow LK. A physiological pharmacokinetic model for morphine disposition in the pregnant rat. J Pharmacokinet Biopharm 1983; 11(2): 147-63.
[45]
Fisher JW, Whittaker TA, Taylor DH, Clewell HJ III, Andersen ME. Physiologically based pharmacokinetic modeling of the pregnant rat: A multiroute exposure model for trichloroethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 1989; 99(3): 395-414.
[46]
Luecke RH, Wosilait WD, Pearce BA, Young JF. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 1994; 49(2): 90-103.
[47]
Clewell HJ, Gearhart JM, Gentry PR, et al. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 1999; 19(4): 547-58.
[48]
Dallmann A, Pfister M, van den Anker J, Eissing T. Physiologically based pharmacokinetic modeling in pregnancy: A systematic review of published models. Clin Pharmacol Ther 2018; 104(6): 1110-24.
[49]
Ariëns EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984; 26(6): 663-8.
[50]
Kulo A, van de Velde M, van Calsteren K, et al. Pharmacokinetics of intravenous ketorolac following caesarean delivery. Int J Obstet Anesth 2012; 21(4): 334-8.
[51]
Sandruck JC, Grobman WA, Gerber SE. The effect of short-term indomethacin therapy on amniotic fluid volume. Am J Obstet Gynecol 2005; 192(5): 1443-5.
[52]
Vanhaesebrouck P, Thiery M, Leroy JG, et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr 1988; 113(4): 738-43.
[53]
Mroszczak EJ, Jung D, Yee J, Bynum L, Sevelius H, Massey I. Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. Pharmacotherapy 1990; 10(6 (Pt 2)): 33S-9S.
[54]
Välitalo PA, Kemppainen H, Kulo A, et al. Body weight, gender and pregnancy affect enantiomer-specific ketorolac pharmacokinetics. Br J Clin Pharmacol 2017; 83(9): 1966-75.
[55]
Kulo A, Smits A, Maleškić S, et al. Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. Bosn J Basic Med Sci 2017; 17(1): 54-60.
[56]
Lapicque F, Muller N, Payan E, Dubois N, Netter P. Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1993; 25(2): 115-23.
[57]
Mroszczak E, Combs D, Chaplin M, et al. Chiral kinetics and dynamics of ketorolac. J Clin Pharmacol 1996; 36(6): 521-39.
[58]
Cohen MN, Christians U, Henthorn T, et al. Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. Anesth Analg 2011; 112(3): 655-60.
[59]
Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60(6): 619-35.
[60]
Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection. JAMA Surg 2017; 152(8): 784-91.
[61]
Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326(5): 281-6.
[62]
van Schalkwyk J, Van Eyk N. No. 247-Antibiotic Prophylaxis in Obstetric Procedures. J Obstet Gynaecol Can 2017; 39(9): e293-9.
[63]
Ansari J, Carvalho B, Shafer SL, Flood P. Pharmacokinetics and pharmacodynamics of drugs commonly used in pregnancy and parturition. Anesth Analg 2016; 122(3): 786-804.
[64]
Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy 2015; 35(11): 1052-62.
[65]
Smaill FM, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev 2014; (10): CD007482.
[66]
Heesen M, Klöhr S, Rossaint R, et al. Concerning the timing of antibiotic administration in women undergoing caesarean section: A systematic review and meta-analysis. BMJ Open 2013; 3(4): 3.
[67]
Mackeen AD, Packard RE, Ota E, Berghella V, Baxter JK. Timing of intravenous prophylactic antibiotics for preventing postpartum infectious morbidity in women undergoing cesarean delivery. Cochrane Database Syst Rev 2014; (12): CD009516.
[68]
Allegaert K, van Mieghem T, Verbesselt R, et al. Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. Am J Obstet Gynecol 2009; 200(2): 170.e1-7.
[69]
Elkomy MH, Sultan P, Drover DR, Epshtein E, Galinkin JL, Carvalho B. Pharmacokinetics of prophylactic cefazolin in parturients undergoing cesarean delivery. Antimicrob Agents Chemother 2014; 58(6): 3504-13.
[70]
Dallmann A, Solodenko J, Ince I, Eissing T. Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women. CPT Pharmacometrics Syst Pharmacol 2018; 7(7): 419-31.
[71]
Horton S, Tuerk A, Cook D, Cook J, Dhurjati P. Maximum Recommended Dosage of Lithium for Pregnant Women Based on a PBPK Model for Lithium Absorption. Adv Bioinforma 2012; 2012: 352729.
[72]
Ke AB, Nallani SC, Zhao P, Rostami-Hodjegan A, Unadkat JD. A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction. CPT Pharmacometrics Syst Pharmacol 2012; 1: e3.
[73]
Dallmann A, Ince I, Coboeken K, Eissing T, Hempel G. A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. Clin Pharmacokinet 2018; 57(6): 749-68.
[74]
Dallmann A, Ince I, Solodenko J, et al. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women. Clin Pharmacokinet 2017; 56(12): 1525-41.
[75]
Philipson A, Stiernstedt G. Pharmacokinetics of cefuroxime in pregnancy. Am J Obstet Gynecol 1982; 142(7): 823-8.
[76]
Mittal P, Wing DA. Urinary tract infections in pregnancy. Clin Perinatol 2005; 32(3): 749-64.
[77]
Bouazza N, Pestre V, Jullien V, et al. Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis. Br J Clin Pharmacol 2012; 74(6): 971-7.
[78]
Baird P, Hughes S, Sullivan M, Willmot I. Penetration into bone and tissues of clindamycin phosphate. Postgrad Med J 1978; 54(628): 65-7.
[79]
Muller AE, Mouton JW, Oostvogel PM, et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother 2010; 54(5): 2175-81.
[80]
Wear CD, Towers CV, Brown MS, Weitz B, Porter S, Wolfe L. Transplacental passage of clindamycin from mother to neonate. J Perinatol 2016; 36(11): 960-1.
[81]
Philipson A, Sabath LD, Charles D. Transplacental passage of erythromycin and clindamycin. N Engl J Med 1973; 288(23): 1219-21.
[82]
Weinstein AJ, Gibbs RS, Gallagher M. Placental transfer of clindamycin and gentamicin in term pregnancy. Am J Obstet Gynecol 1976; 124(7): 688-91.
[83]
Stéen B, Rane A. Clindamycin passage into human milk. Br J Clin Pharmacol 1982; 13(5): 661-4.
[84]
Pacifici GM. Placental transfer of antibiotics administered to the mother: A review. Int J Clin Pharmacol Ther 2006; 44(2): 57-63.
[85]
Drug Use in Pregnancy and the First Year of Life 2014. Wiley Editing Ed: Dr Sean B Ainsworth.
[86]
Ehteshami Bejnordi B, Veta M, Johannes van Diest P, et al. Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer. JAMA 2017; 318(22): 2199-210.
[87]
Raghupathi W, Raghupathi V. Big data analytics in healthcare: Promise and potential. Health Inf Sci Syst 2014; 2: 3.
[88]
Wang W, Krishnan E. Big data and clinicians: A review on the state of the science. JMIR Med Inform 2014; 2(1): e1.
[89]
Kuepfer L, Niederalt C, Wendl T, et al. Applied concepts in PBPK modeling: How to build a PBPK/PD model. CPT Pharmacometrics Syst Pharmacol 2016; 5(10): 516-31.
[90]
van Hasselt JG, Allegaert K, van Calsteren K, Beijnen JH, Schellens JH, Huitema AD. Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy. BioMed Res Int 2014; 2014: 897216.
[91]
Moran P, Baylis PH, Lindheimer MD, Davison JM. Glomerular ultrafiltration in normal and preeclamptic pregnancy. J Am Soc Nephrol 2003; 14(3): 648-52.
[92]
Krutzén E, Olofsson P, Bäck SE, Nilsson-Ehle P. Glomerular filtration rate in pregnancy: A study in normal subjects and in patients with hypertension, preeclampsia and diabetes. Scand J Clin Lab Invest 1992; 52(5): 387-92.
[93]
Hays PM, Cruikshank DP, Dunn LJ. Plasma volume determination in normal and preeclamptic pregnancies. Am J Obstet Gynecol 1985; 151(7): 958-66.
[94]
Käär K, Jouppila P, Kuikka J, Luotola H, Toivanen J, Rekonen A. Intervillous blood flow in normal and complicated late pregnancy measured by means of an intravenous 133Xe method. Acta Obstet Gynecol Scand 1980; 59(1): 7-10.
[95]
Delaney SR, Malik PRV, Stefan C, Edginton AN, Colantonio DA, Ito S. Predicting escitalopram exposure to breastfeeding infants: Integrating analytical and in silico techniques. Clin Pharmacokinet 2018; 57(12): 1603-11.
[96]
Willmann S, Edginton AN, Coboeken K, Ahr G, Lippert J. Risk to the breast-fed neonate from codeine treatment to the mother: A quantitative mechanistic modeling study. Clin Pharmacol Ther 2009; 86(6): 634-43.
[97]
Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368(9536): 704.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 5
Year: 2019
Page: [483 - 495]
Pages: 13
DOI: 10.2174/1381612825666190320135137
Price: $58

Article Metrics

PDF: 53
HTML: 8
EPUB: 1
PRC: 1